. He was followed by Benjamin Sarfati in France and Hung-Wen Lai in Taiwan. In March 2018, Neil Tanna performed the first procedure in the United States. The Erasto Gaertner Hospital, in Curitiba, has its robotic surgery program since December 2016 in the areas of oncological surgery of the urinary tract, digestive tract and gynecology; and on January 29 th , 2019 we performed the first breast procedure, a breast and nipple-sparing mastectomy with immediate reconstruction, thus creating a new option for patients who are candidates for risk-reducing surgeries and early cases of breast cancer.
Traditional surgery requires incisions in the breast, while robotic surgery, in an innovative way, uses this new technology, allowing the procedure to be carried out by a small incision (3 cm) outside the breast, with visual access extended to remote parts of the breast, increasing safety and negligible bleeding.
With regard to plastic reconstruction, although robotics is still in the embryonic stage, it is quite promising. Traditionally, large dorsal and rectal abdominal flaps require large incisions for dissection. This is a perfect example of the great benefit of robotics, using minimally invasive surgery and significantly reducing scarring of the flap, which even with the use of conventional laparoscopy is not possible because of difficulties in visualization and limitation of movement of the instruments. Micropins, microdoppler probes and hydrojet dissectors are already available, instruments which will increase the use of robots in the field of reconstructive plastic surgery. It should be noted here that the robotic platform also adds magnification with manipulation without tremor 8 . There are almost 5,000 Da Vinci equipment around the world, more than 43,000 trained surgeons and about 5 million surgeries done. In addition, since 1998 we have more than 15,000 publications on robotic procedures. In Brazil, so far, we have 55 Da Vinci systems installed in 46 hospitals and 1 training center.
Cost is still the main constraint for robotic surgery at the moment. The initial investment is about 1.5 million dollars for the equipment, about 2 to 3 thousand dollars in instrument per intervention and about 100 thousand dollars per year for maintenance of the equipment. However, Intuitive's patent is about to fall and new competitors must enter the market, bringing costs to more acceptable levels. The launch of two new equipment, by Medtronic and by Johnson and Johnson, are expected this year.
So, is robotic surgery worth to be used on breast procedures? Like all new technology, we believe that its use should grow over time, always with precise indications. It is another feature that adds to our arsenal in search of the best therapeutic result and the self-esteem of our patients.
Do mastologists need to worry about taking this training? Tough question. Perhaps in large centers that already have robotic programs it is worth developing the experience and using this additional resource. But there is no doubt that the technology has come to stay and that its progress will bring more and more indications and instrumental options.
Let us all be prepared for the future! And may the science be with you!
